Introduction to Bioanalysis and Regulatory Framework

Definition and Scope Bioanalysis is defined as the quantitative measurement of drugs, whether small molecules or biological therapeutics, and their...

Definition and Scope

Bioanalysis is defined as the quantitative measurement of drugs, whether small molecules or biological therapeutics, and their metabolites in biological fluids or tissues. It provides the scientific backbone for pharmacokinetic studies that characterise the absorption, distribution, metabolism, and excretion of a drug candidate, for pharmacodynamic studies that relate drug exposure to biological effect, for toxicokinetic studies conducted in preclinical species, and for bioequivalence studies that compare generic and innovator formulations. Each of these study types is mandated by regulatory agencies, including the Central Drugs Standard Control Organisation, the United States Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency, as a prerequisite for the approval of a new or generic pharmaceutical product.

Categories of Bioanalytical Studies

Bioanalytical studies span a range of designs tailored to distinct scientific questions. Single-dose and multiple-dose pharmacokinetic studies in Phase I clinical development establish dose linearity, half-life, and steady-state behaviour. Bioequivalence studies compare the rate and extent of absorption of a generic formulation against an innovator reference product, generally requiring the ninety percent confidence interval for the geometric mean ratio of the area under the curve and maximum concentration to fall within eighty to one hundred twenty-five percent of the reference value. Bioavailability studies establish the absolute or relative fraction of an administered dose that reaches the systemic circulation, toxicokinetic studies in preclinical species characterise systemic exposure in relation to observed toxicity, drug-drug interaction studies assess the effect of a co-administered agent on the pharmacokinetic parameters of the drug of interest, metabolite profiling studies identify and quantify circulating metabolites in accordance with metabolites in safety testing considerations, and tissue distribution studies characterise drug concentration within target and non-target organs.

Regulatory Perspective

Bioanalytical study design and conduct are governed by International Council for Harmonisation guideline M10 on bioanalytical method validation, together with region-specific guidance issued by the United States Food and Drug Administration and the European Medicines Agency, which collectively harmonise expectations regarding validation parameters, acceptance criteria, and documentation across regulatory jurisdictions.